University of California, San Francisco

Rise in Cyber Attacks Demand Increased Investment in Zero Trust Security

Retrieved on: 
Monday, February 7, 2022
Zero, GLOBE, Architecture, Industry, Password management, Pulse, Bell–LaPadula model, San Francisco, Standstill, University of California, San Francisco, ID, Verizon Communications, Technology, University, Information, Security, Hitachi, Organization, The Power of One, Privilege (evidence), Education, Online shopping, Weapon, Risk management

While organizations increasingly understand the need for a Zero Trust security approach that will protect them from insider and outsider threats, the majority are slow to make real changes to their security postures.

Key Points: 
  • While organizations increasingly understand the need for a Zero Trust security approach that will protect them from insider and outsider threats, the majority are slow to make real changes to their security postures.
  • With a Zero Trust approach, businesses are empowered with contextual, adaptive, just-in-time access that tightens defenses.
  • Perimeter defense and endpoint security are important, but an over-reliance on such measures leaves organizations vulnerable to attacks.
  • An agile, phased approach is needed to transform legacy systems to a Zero Trust Architecture while meeting demands of an evolving industry.

Study: Cognitive Assessments Can Help Track Cardio Risk Patients

Retrieved on: 
Monday, February 7, 2022
Hypertension, GLOBE, Medicare, Library, Memory, JMIR, Quality of life, Dementia, Risk, University of California, San Francisco, SAN, Patient, University, Atrial fibrillation, Â, Posit Science Corporation, Association, Hope, Cognition, Attention, Health, Medical device, Dietary supplement

SAN FRANCISCO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- A new study is the first to show that a remote cognitive assessment could help with tracking patients with cardiovascular risk.

Key Points: 
  • SAN FRANCISCO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- A new study is the first to show that a remote cognitive assessment could help with tracking patients with cardiovascular risk.
  • Prior studies have established that people with cardiovascular risk factors are at increased risk for cognitive decline and dementia as they age.
  • The Health eBrain Study, published in JMIR Formative Research , enrolled and assessed 239 older adults in a proof-of-concept trial to determine if novel, remotely-administered, cognitive assessments could detect the known association between cognitive performance and cardiovascular risk factors.
  • It also raises the possibility that health systems and providers could identify patients with cardiovascular risk factors based on their remotely-administered brain health assessments, as well as monitor the cognitive ability of patients with such risk factors.

Boundless Bio Appoints Amy Berkley, Ph.D., as Vice President, Program Team Leadership and Strategic Alliances

Retrieved on: 
Monday, February 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Rolling circle replication, Program Manager, Program, Leadership, Boundless, Gene amplification, Patient, University, Halozyme, Ionis Pharmaceuticals, Bio, DNA, David Geffen School of Medicine at UCLA, Therapy, Head, Cardiology, Cancer, University of California, San Francisco, University of California, San Diego, Doctor of Philosophy, Management, Pharmaceutical industry, Ionis

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Amy Berkley has been appointed as Vice President of Program Team Leadership and Strategic Alliances.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Amy Berkley has been appointed as Vice President of Program Team Leadership and Strategic Alliances.
  • We are excited to have Amy join the team, said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
  • Prior to joining Boundless Bio, Amy served as Head of Alliance Management at Ionis Pharmaceuticals, where she managed over 30 programs with pharmaceutical and biotech partners from discovery through clinical development.
  • Boundless Bio is one of the most exciting and innovative companies in precision oncology today, said Dr. Berkley.

Scientists Reveal "Rosetta Stone" of Immune Cell Function

Retrieved on: 
Friday, February 4, 2022
DNA, Digestive, Byers, Cell, SAN, Biohub, Infection, University, MD, CRISPR, Simons Foundation Autism Research Initiative, Gladstone Institutes, UCSF, National Institute of Diabetes and Digestive and Kidney Diseases, Immunotherapy, Cytokine, Technology, Inflammation, Efficiency, Research, National, Degenerative disease, Kidney, Marson, Cancer, Simons Foundation, Burroughs Wellcome Fund, Gene, Genome, S10, Cas9, Immunity, Doctor of Philosophy, Rosetta Stone, San Francisco, Cancer Research Institute, University of California, San Francisco, Protein, National Institutes of Health, CRISPR interference, Monocyte, National Institute, Vaccine, Pharmaceutical industry, Antibiotics, Microscope, Science

Now, researchers at Gladstone Institutes and UC San Francisco (UCSF) have adapted the CRISPRa system to human immune cells.

Key Points: 
  • Now, researchers at Gladstone Institutes and UC San Francisco (UCSF) have adapted the CRISPRa system to human immune cells.
  • This new tool gives them a more thorough and rapid way to discover genes that play a role in immune cell biology than previously possible.
  • "These CRISPRa experiments create a Rosetta Stone for understanding which genes are important for every function of immune cells.
  • The scientists activated each gene in the genome in different cells, enabling them to test almost 20,000 genes in parallel.

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Retrieved on: 
Thursday, February 3, 2022
Awareness, Growth, Pregnancy, Anxiety, Safety, Legislation, CEO, Biological engineering, Patient, MacArthur Fellows Program, Sale, Food, SEDAR, MAPS, University, Genentech, Biotechnology, Medicinal chemistry, Digital technology, Technology, University of California, San Francisco, Research, PATH (global health organization), NEO, COVID-19, Doctor of Philosophy, Woman, Board, Experiment, Jeffrey Skoll, Schwab Foundation for Social Entrepreneurship, Medicine, Mental health, Public health, Company, Multidisciplinary Association for Psychedelic Studies, GLOBE, Addiction, FSE, News, Phrase, Depression, Regulation of tobacco by the U.S. Food and Drug Administration, Drug development, San Francisco, FDA, Therapy, Director, OTC, PTSD, Skoll Foundation, Pharmaceutical industry, Management, Risk management, Ashoka

We are thrilled to welcome Dr. Hale to Mydecine's board of directors.

Key Points: 
  • We are thrilled to welcome Dr. Hale to Mydecine's board of directors.
  • Strengthening our board with industry leaders like Victoria is one of the ways Mydecine is preparing for future growth.
  • Like the team at Mydecine, Victoria has a strong passion for working to improve public health outcomes, said Mydecine CEO Josh Bartch.
  • There is a tremendous unmet need for effective treatments for mental health disorders, said Dr. Hale, who will join the Companys Board of Directors mid-February.

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

Retrieved on: 
Wednesday, February 2, 2022
CNS, Medical Center, Principal, Part, Forward-looking statement, ADHD, Patient, NASDAQ, University, University of California, San Francisco, Trial of the century, SEC, UCSF, Distribution, Cedars-Sinai Medical Center, Technology, US, Part Two, Attention deficit hyperactivity disorder, Population, CAGR, Hospital, Stimulant, Taipei Veterans General Hospital, U.S. Securities and Exchange Commission, Demography, Company, Risk, Stanford University, GLOBE, ITT, Ophthalmology, Phase, Drug development, San Francisco, Comment, National Taiwan University Hospital, Security (finance), CA, Pharmaceutical industry, Adult

Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.

Key Points: 
  • Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022.
  • This randomized, double-blind, placebo-controlled Part 2 study involves a total of approximately 100 patients from the United States and Taiwan.
  • The results from the Part 1 study demonstrated the therapeutic value of PDC-1421 and support further clinical development of ABV-1505 for the treatment of ADHD.
  • We expect to have a productive discussion finalizing the Part 2 study protocol on February 14th, said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma.

PreludeDx™ Announces the Appointment of Derek J. Maetzold of Castle Biosciences to its Board of Directors

Retrieved on: 
Wednesday, February 2, 2022
CEO, Breast, Risk, Patient, George Mason University, University, University of California, San Francisco, Cancer, National, Physician, Molecular biology, National Cancer Institute, FCB, Compugen (Israeli company), Twitter, Technology, Adoption, Board of directors, Woman, Research, Board, Instagram, Recurrence, Program, Schering-Plough, DCIS, Biomarker, Precision medicine, Company, Risk assessment, University of California, Riverside, AstraZeneca, Ductal carcinoma, Amylin Pharmaceuticals, Breast cancer, LinkedIn, MBA, Convergence of random variables, Management, Medical imaging, Pharmaceutical industry, Biology, Pfizer, Facebook, Merck, Novartis

"I am pleased to welcome Derek to our Board of Directors.

Key Points: 
  • "I am pleased to welcome Derek to our Board of Directors.
  • "I am impressed with PreludeDx's DCISionRT test, the only test that predicts radiation therapy benefit and risk of recurrence for ductal carcinoma in situ (DCIS) breast cancer patients," said Derek J. Maetzold.
  • Mr. Maetzold spent the 24 years prior to founding Castle Biosciences in the pharmaceuticals with a focus on business licensing and commercial oversight of pre-approved therapies.
  • For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

New Publication in Science Leverages Rebus Esper Platform to Create Cell Atlas of Brain Vasculature

Retrieved on: 
Thursday, January 27, 2022
Biotechnology, Technology, Health, Mental Health, Medical Devices, Research, Software, Surgery, Genetics, Science, Hardware, High, Blood, Adult, Â, High fidelity, Gene, Brain, Fidelity, UCSF, Research, University, Technology, Silicon, Stroke, Ageing, Lipofuscin, Cerebral cortex, Pectus carinatum, Environment, Cell, University of California, San Francisco, Patient, Gene expression, Lists of diseases, Unified school district, Map, Neurosurgery, Vaccine, Medical imaging, Rebus, Neuroscience, Science

They compared these cells with samples from healthy adult brain blood vessels to determine which genes were being expressed in the differing samples.

Key Points: 
  • They compared these cells with samples from healthy adult brain blood vessels to determine which genes were being expressed in the differing samples.
  • Finally, they created a comprehensive cell atlas of the vascular system in the brain.
  • The study, titled A single-cell atlas of the normal and malformed human brain vasculature was published today in the January 27 issue of Science.
  • Rebus Biosystems provides all-inclusive assay kits to empower researchers with the resolution, scale and speed of the Rebus Esper for multiple applications.

Lunaphore appoints Alice Feng as Chief Financial Officer

Retrieved on: 
Thursday, January 27, 2022
Science, Biotechnology, Research, Oncology, Health, Aerospace, Manufacturing, Other Health, Research, Growth, Aetna, Genetics, Scripps Research, Microbiology, Business economics, University, University of California, San Francisco, Technology, Multimedia, Merrill (company), Economics, Neoplasm, Acquisition, Scripps Health, Corporate development, Management

Lunaphore , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced that Alice T. Feng will join the Lunaphore leadership team as Chief Financial Officer, effective January 31, 2022.

Key Points: 
  • Lunaphore , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced that Alice T. Feng will join the Lunaphore leadership team as Chief Financial Officer, effective January 31, 2022.
  • We are excited to work with Alice to achieve Lunaphores ambitious goals as we bring spatial biology into the mainstream.
  • Ms. Feng most recently served as Chief Financial Officer of Scripps Research, a world-renowned biomedical research institution in San Diego, California.
  • In this role, Ms. Feng was an instrumental member of the executive team that supported all of Scripps financial strategy and operations.

Mutant Stem Cells Defy Rules of Development

Retrieved on: 
Wednesday, January 26, 2022
University, UCSF, Finger, Blood, CRISPR, Gene, National, Pediatrics, Research, American Heart Association, B cell, University of California, San Francisco, Stem cell, Bruneau, Mesoderm, Society, Cell, San Francisco, SAN, Adult, Muscle, Gladstone Institutes, Character, Heart, Brahma, Tissue, Technology, Cardiovascular disease, Doctor of Philosophy, Ventricular septal defect, Environment, University of California, San Francisco Fetal Treatment Center, Embryonic stem cell, Disease, Heart failure, Cancer, Mobile phone, Medical imaging, Vaccine, Satellite navigation device, Pharmaceutical industry, William Ewart Gladstone, Nature, MD

It sounds like a practical joke, but this kind of shocking transformation is what really happened to a dish of mouse stem cells when scientists at Gladstone Institutes removed just one genestem cells destined to become heart cells suddenly resembled the precursors to brain cells.

Key Points: 
  • It sounds like a practical joke, but this kind of shocking transformation is what really happened to a dish of mouse stem cells when scientists at Gladstone Institutes removed just one genestem cells destined to become heart cells suddenly resembled the precursors to brain cells.
  • On their path to becoming heart cells, for instance, embryonic stem cells first differentiate into mesoderm, one of three primitive tissues found in the earliest embryos.
  • A decade ago, Gladstone Senior Investigator Shinya Yamanaka, MD, PhD, discovered how to reprogram fully differentiated adult cells into induced pluripotent stem cells.
  • In particular, mesoderm cells could not become the precursors of such distant types as brain cells or gut cells.